Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 22-Aug-23 3:57 PM View:  | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 21-Aug-23 | Private Purchase | 15,335 | $1.30 | $19,992.20 | 2% 745.94K to 761.28K | |
| 18-Aug-23 7:05 AM View: | Duncan Gregory Scott Chief Executive Officer Director | Virios Therapeutics, Inc. (VIRI) | 17-Aug-23 | Private Purchase | 25,000 | $1.25 | $31,245.00 | 77% 32.46K to 57.46K | |
| 12-Dec-22 1:39 PM View: | Whitley Richard James Director | Virios Therapeutics, Inc. (VIRI) | 08-Dec-22 | Sale | 1,800 | $0.26 | $466.38 | (72%) 2.5K to 0.7K | |
| 24-May-22 10:24 AM View: | Duncan Gregory Scott Chief Executive Officer Director | Virios Therapeutics, Inc. (VIRI) | 23-May-22 | Private Purchase | 7,500 | $4.52 | $33,900.00 | 30% 24.96K to 32.46K | |
| 24-May-22 2:53 PM View: | Walsh Angela SVP OF FINANCE | Virios Therapeutics, Inc. (VIRI) | 23-May-22 | Private Purchase | 2,000 | $4.57 | $9,150.00 | 200% 1.0K to 3.0K | |
| 19-May-22 11:48 AM View: | Whitley Richard James Director | Virios Therapeutics, Inc. (VIRI) | 18-May-22 | Private Purchase | 500 | $4.53 | $2,262.50 | 25% 2.0K to 2.5K | |
| 19-May-22 11:44 AM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 18-May-22 | Private Purchase | 241 | $4.50 | $1,084.50 | < 1% 745.7K to 745.94K | |
| 18-May-22 11:24 AM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 17-May-22 | Private Purchase | 13,450 | $4.38 | $58,913.70 | 2% 732.25K to 745.7K | |
| 30-Mar-22 11:55 AM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 29-Mar-22 | Private Purchase | 600 | $4.94 | $2,964.48 | < 1% 731.65K to 732.25K | |
| 24-Mar-22 2:52 PM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 23-Mar-22 | Market Purchase | 2,197 | $5.46 | $12,001.60 | < 1% 729.46K to 731.65K | 5% |
| 28-Jan-22 3:30 PM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 27-Jan-22 | Market Purchase | 4,180 | $5.98 | $24,997.70 | < 1% 725.28K to 729.46K | (4%) |
| 07-Jan-22 5:24 PM View: | de la Rosa Abel Director | Virios Therapeutics, Inc. (VIRI) | 07-Jan-22 | Market Purchase | 4,000 | $5.90 | $23,584.00 | 100% 0 to 4.0K | (< 1%) |
| 07-Jan-22 1:14 PM View: | Whitley Richard James Director | Virios Therapeutics, Inc. (VIRI) | 06-Jan-22 | Market Purchase | 1,800 | $5.72 | $10,296.00 | 900% 0.2K to 2.0K | 2% |
| 05-Jan-22 3:12 PM View: | Keefer David R Director | Virios Therapeutics, Inc. (VIRI) | 04-Jan-22 | Market Purchase | 5,000 | $5.80 | $28,975.00 | 64% 7.81K to 12.81K | (2%) |
| 04-Jan-22 3:19 PM View: | Thomas John C Director | Virios Therapeutics, Inc. (VIRI) | 04-Jan-22 | Market Purchase | 1,000 | $5.65 | $5,650.00 | 100% 0 to 1.0K | < 1% |
| 04-Jan-22 3:23 PM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 03-Jan-22 | Market Purchase | 2,215 | $5.43 | $12,033.90 | < 1% 723.06K to 725.28K | 4% |
| 23-Dec-21 3:59 PM View: | Whitley Richard James Director | Virios Therapeutics, Inc. (VIRI) | 23-Dec-21 | Market Purchase | 200 | $5.72 | $1,145.00 | 100% 0 to 0.2K | < 1% |
| 22-Dec-21 1:23 PM View: | Duncan Gregory Scott Chief Executive Officer Director | Virios Therapeutics, Inc. (VIRI) | 21-Dec-21 | Market Purchase | 5,000 | $5.52 | $27,615.00 | 25% 19.96K to 24.96K | 5% |
| 22-Dec-21 1:28 PM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 21-Dec-21 | Market Purchase | 8,827 | $5.66 | $49,997.00 | 1% 714.23K to 723.06K | 2% |
| 09-Jul-21 1:36 PM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 07-Jul-21 | Market Purchase (Planned) | 942 | $6.32 | $5,950.61 | < 1% 713.29K to 714.23K | (4%) |
| 07-Apr-21 1:59 PM View: | Duncan Gregory Scott Chief Executive Officer Director | Virios Therapeutics, Inc. (VIRI) | 06-Apr-21 | Market Purchase (Planned) | 382 | $6.36 | $2,428.60 | 2% 19.58K to 19.96K | (4%) |
| 06-Apr-21 3:38 PM View: | Duncan Gregory Scott Chief Executive Officer Director | Virios Therapeutics, Inc. (VIRI) | 05-Apr-21 | Market Purchase (Planned) | 15,675 | $6.17 | $96,757.10 | 402% 3.9K to 19.58K | 3% |
| 01-Feb-21 7:54 PM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 29-Jan-21 | Market Purchase | 3,500 | $7.47 | $26,145.00 | < 1% 727.99K to 731.49K | (9%) |
| 01-Feb-21 7:54 PM View: | Keefer David R Director | Virios Therapeutics, Inc. (VIRI) | 28-Jan-21 | Option Exercise | 1,602 | $7.80 | $12,495.60 | 26% 6.21K to 7.81K | (13%) |
| 01-Feb-21 7:54 PM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 28-Jan-21 | Option Exercise | 801 | $7.80 | $6,247.80 | < 1% 727.19K to 727.99K | (13%) |
| 01-Feb-21 7:54 PM View: | Walsh Angela VP of Finance | Virios Therapeutics, Inc. (VIRI) | 28-Jan-21 | Market Purchase | 1,000 | $7.30 | $7,300.00 | 100% 0 to 1.0K | (7%) |
| 08-Jan-21 7:23 PM View: | Duncan Gregory Scott Chief Executive Officer Director | Virios Therapeutics, Inc. (VIRI) | 06-Jan-21 | Option Exercise | 801 | $7.80 | $6,247.80 | 26% 3.1K to 3.9K | 9% |
| 21-Dec-20 8:10 PM View: | Pridgen William Director | Virios Therapeutics, Inc. (VIRI) | 17-Dec-20 | Purchase | 1,500 | $11.98 | $17,970.00 | < 1% 725.69K to 727.19K |
